Stanley Erck, Novavax CEO (Lee Jin-wook/Yonhap via AP Images)
May 10, 2022 09:40 AM EDTUpdated 11:07 AM
Pharma
Coronavirus

Af­ter rack­ing up 41 Covid jab nods out­side US, No­vavax hits first prof­itable quar­ter but still dis­ap­points in­vestors

Kyle LaHucik

Senior Reporter

About four weeks be­fore FDA’s out­side ad­vi­sors are slat­ed to re­view No­vavax’s Covid-19 jab af­ter a long, fed­er­al­ly-fund­ed and wind­ing jour­ney that was all …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times